AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32428059 — intervention group
Group type: COMPARATOR
Intervention: CP
Number of subjects: 100
Study 34372971 — intervention group
Group type: EXPERIMENTAL
Intervention: C/P + T (carboplatin/paclitaxel + trastuzumab)
Number of subjects: 60
Study 34372971 — intervention group
Group type: COMPARATOR
Intervention: C/P (carboplatin/paclitaxel)
Number of subjects: 60
Study 34372971 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab maintenance therapy
Number of subjects: 60
Study 32005476 — intervention group
Group type: EXPERIMENTAL
Intervention: Humorous video (H)
Number of subjects: 38
Study 32005476 — intervention group
Group type: COMPARATOR
Intervention: Unhumorous video (U)
Number of subjects: 38
Study 35562555 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP plus standard cardiovascular care
Number of subjects: 102
Study 35562555 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone (UC group)
Number of subjects: 102
Study 33979843 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized homeopathic treatment
Number of subjects: 7
Study 32303413 — intervention group
Group type: EXPERIMENTAL
Intervention: High-efficiency hemodialysis (HED)
Number of subjects: 10
Study 32303413 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodiafiltration (HDF)
Number of subjects: 10
Study 32303413 — intervention group
Group type: EXPERIMENTAL
Intervention: High-efficiency hemodialysis (HED) and Hemodiafiltration (HDF)
Number of subjects: 10
Study 34392336 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm derivation group (n=457)
Number of subjects: 918
Study 34392336 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm validation group (n=461)
Number of subjects: 918
Study 34392336 — intervention group
Group type: EXPERIMENTAL
Intervention: Without baseline risk-stratifier
Number of subjects: 918
Study 34159386 — intervention group
Group type: EXPERIMENTAL
Intervention: Difficulty waking up for school among JHS boys
Number of subjects: 100050
Study 34159386 — intervention group
Group type: EXPERIMENTAL
Intervention: Difficulty waking up for school among JHS girls
Number of subjects: 100050
Study 34159386 — intervention group
Group type: EXPERIMENTAL
Intervention: Difficulty waking up for school among SHS boys
Number of subjects: 100050
Study 34159386 — intervention group
Group type: EXPERIMENTAL
Intervention: Difficulty waking up for school among SHS girls
Number of subjects: 100050
Study 34159386 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for school tardiness
Number of subjects: 100050
Study 34159386 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for school absence
Number of subjects: 100050
Study 34159386 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly smoking days for JHS girls
Number of subjects: 100050
Study 35457447 — intervention group
Group type: COMPARATOR
Intervention: Anodal tDCS
Number of subjects: 0
Study 35457447 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate (MPH)
Number of subjects: 0
Study 34133657 — intervention group
Group type: COMPARATOR
Intervention: Home-based training
Number of subjects: 23
Study 34133657 — intervention group
Group type: EXPERIMENTAL
Intervention: Center-based training
Number of subjects: 23
Study 35069955 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg (S group)
Number of subjects: 88
Study 35069955 — intervention group
Group type: COMPARATOR
Intervention: Control group (C group)
Number of subjects: 88
Study 32852294 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% chloroprocaine (CP)
Number of subjects: 70
Study 32852294 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine with 150 µg epinephrine, 2 mL of 8.4% bicarbonate, and 100 µg fentanyl (LEBF)
Number of subjects: 70
Study 33682592 — intervention group
Group type: EXPERIMENTAL
Intervention: Heartfulness meditation
Number of subjects: 155
Study 33682592 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 155
Study 32472742 — intervention group
Group type: EXPERIMENTAL
Intervention: NEPA (single oral dose)
Number of subjects: 667
Study 32472742 — intervention group
Group type: COMPARATOR
Intervention: APR/GRAN (3-day regimen)
Number of subjects: 667
Study 34452673 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief motivational intervention plus behavioral activation (BMI + BA)
Number of subjects: 113
Study 34452673 — intervention group
Group type: COMPARATOR
Intervention: Brief motivational intervention plus supportive counseling (BMI + SC)
Number of subjects: 113
Study 34452673 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI + BA
Number of subjects: 113
Study 616681197 — intervention group
Group type: EXPERIMENTAL
Intervention: Olopatadine HCl 0.77%
Number of subjects: 448
Study 616681197 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 448
Study 616681197 — intervention group
Group type: COMPARATOR
Intervention: Olopatadine 0.2%
Number of subjects: 448
Study 35536391 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-assisted compression (PAC)
Number of subjects: 444
Study 35536391 — intervention group
Group type: COMPARATOR
Intervention: Standard compression (SC)
Number of subjects: 444
Study 33857782 — intervention group
Group type: EXPERIMENTAL
Intervention: Decontamination process (time, dry heat, or ultraviolet C light [UVC])
Number of subjects: 15
Study 33857782 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat treatment
Number of subjects: 15
Study 33857782 — intervention group
Group type: EXPERIMENTAL
Intervention: UVC treatment
Number of subjects: 15
Study 34809479 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasiglucagon autoinjector
Number of subjects: 54
Study 33863564 — intervention group
Group type: EXPERIMENTAL
Intervention: 100μg selenium tablet twice a day for 6 months
Number of subjects: 30
Study 33863564 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets (100μg of starch) twice a day for 6 months
Number of subjects: 30
Study 34360460 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium supplementation for one week
Number of subjects: 19
Study 34360460 — intervention group
Group type: COMPARATOR
Intervention: Usual diet (Control)
Number of subjects: 19
Study 34360460 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium supplementation
Number of subjects: 19
Study 32213226 — intervention group
Group type: COMPARATOR
Intervention: Normal Glucose Tolerance (NGT)
Number of subjects: 1500
Study 32213226 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediabetes
Number of subjects: 1500
Study 32213226 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 Diabetes Mellitus (T2DM)
Number of subjects: 1500
Study 32213226 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 1500
Study 32213226 — intervention group
Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 1500
Study 32213226 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D deficiency
Number of subjects: 1500
Study 35743485 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation (PBM) treatment with a diode laser (810 nm, 6 J/cm2) for 6 weeks (1 session per week)
Number of subjects: 60
Study 35743485 — intervention group
Group type: COMPARATOR
Intervention: Placebo control (simulated treatment)
Number of subjects: 60
Study 33564816 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher relative protein intake
Number of subjects: 65164
Study 33564816 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased relative fat intake
Number of subjects: 65164
Study 33054724 — intervention group
Group type: EXPERIMENTAL
Intervention: Precision early ambulation (PEA)
Number of subjects: 178
Study 33054724 — intervention group
Group type: COMPARATOR
Intervention: Routine ambulation (Control)
Number of subjects: 178
Study 34736908 — intervention group
Group type: EXPERIMENTAL
Intervention: Parecoxib
Number of subjects: 213
Study 34736908 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib
Number of subjects: 213
Study 34736908 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone
Number of subjects: 213
Study 33053561 — intervention group
Group type: EXPERIMENTAL
Intervention: Subthreshold EPM PRP
Number of subjects: 28
Study 33053561 — intervention group
Group type: COMPARATOR
Intervention: Threshold PASCAL PRP
Number of subjects: 28
Study 32915975 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone)
Number of subjects: 729
Study 34172554 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfetalness (self-assessment method)
Number of subjects: 39865
Study 34172554 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 39865
Study 34172554 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfetalness
Number of subjects: 39865
Study 34172554 — intervention group
Group type: COMPARATOR
Intervention: Mindfetalness vs Routine care
Number of subjects: 39865
Study 35767166 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist protocol
Number of subjects: 550
Study 33314807 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced protocol (30 shocks/min, 1,200 shocks/session)
Number of subjects: 404
Study 33314807 — intervention group
Group type: COMPARATOR
Intervention: Standard protocol (60 shocks/min, 2,400 shocks/session)
Number of subjects: 404
Study 33314807 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced protocol
Number of subjects: 404
Study 33314807 — intervention group
Group type: COMPARATOR
Intervention: Standard protocol
Number of subjects: 404
Study 35217436 — intervention group
Group type: EXPERIMENTAL
Intervention: UROX® Junior
Number of subjects: 0
Study 33534940 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a (IFNβ-1a) for 40 weeks
Number of subjects: 0
Study 33534940 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 16 weeks followed by Interferon beta-1a (IFNβ-1a) for 24 weeks
Number of subjects: 0
Study 33534940 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a (IFNβ-1a) for 40 weeks (originally treated group)
Number of subjects: 0
Study 32744555 — intervention group
Group type: EXPERIMENTAL
Intervention: Cripp's Pink apple consumption
Number of subjects: 30
Study 32744555 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenolic compounds in skin and flesh of apples
Number of subjects: 30
Study 35861012 — intervention group
Group type: EXPERIMENTAL
Intervention: Be a Mom, a self‐guided web‐based cognitive behavioral therapy intervention
Number of subjects: 367
Study 35861012 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 367
Study 34684639 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate calorie and protein restriction program (IA)
Number of subjects: 100
Study 34684639 — intervention group
Group type: COMPARATOR
Intervention: Control group (CA)
Number of subjects: 100
Study 32700421 — intervention group
Group type: COMPARATOR
Intervention: Ertugliflozin
Number of subjects: 0
Study 34702382 — intervention group
Group type: EXPERIMENTAL
Intervention: Septoplasty with radiofrequency ablation (group A)
Number of subjects: 74
Study 34702382 — intervention group
Group type: COMPARATOR
Intervention: Septoplasty alone (group B)
Number of subjects: 74
Study 34702382 — intervention group
Group type: COMPARATOR
Intervention: Comparison between group A and group B
Number of subjects: 74
Study 33275085 — intervention group
Group type: EXPERIMENTAL
Intervention: 78 years old + poor physical health
Number of subjects: 147
Study 33275085 — intervention group
Group type: EXPERIMENTAL
Intervention: 78 years old + normal physical health
Number of subjects: 147
Study 33275085 — intervention group
Group type: EXPERIMENTAL
Intervention: 48 years old + poor physical health
Number of subjects: 147
Study 33275085 — intervention group
Group type: EXPERIMENTAL
Intervention: 48 years old + normal physical health
Number of subjects: 147
Study 33528919 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention plus liraglutide 3.0 mg
Number of subjects: 78
Study 33528919 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle intervention alone
Number of subjects: 78
Study 33528919 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (after controlling for weight loss)
Number of subjects: 78
Study 32374724 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated depression screening and treatment program (Friendship Bench therapy and antidepressants)
Number of subjects: 0
Study 32374724 — intervention group
Group type: COMPARATOR
Intervention: Control phase (screening-only)
Number of subjects: 0
Study 36034448 — intervention group
Group type: EXPERIMENTAL
Intervention: YPEG-rhGH 100 μg/kg/week
Number of subjects: 43
Study 36034448 — intervention group
Group type: EXPERIMENTAL
Intervention: YPEG-rhGH 120 μg/kg/week
Number of subjects: 43
Study 36034448 — intervention group
Group type: EXPERIMENTAL
Intervention: YPEG-rhGH 140 μg/kg/week
Number of subjects: 43
Study 36034448 — intervention group
Group type: COMPARATOR
Intervention: Daily rhGH 35 μg/kg/day
Number of subjects: 43
Study 36034448 — intervention group
Group type: EXPERIMENTAL
Intervention: YPEG-rhGH (all doses)
Number of subjects: 43
Study 36034448 — intervention group
Group type: EXPERIMENTAL
Intervention: YPEG-rhGH
Number of subjects: 43
Study 34465327 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (20 mg/kg)
Number of subjects: 450
Study 34465327 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 450
Study 32692805 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional intervention (IG)
Number of subjects: 4631
Study 32692805 — intervention group
Group type: COMPARATOR
Intervention: Routine care (CG)
Number of subjects: 4631
Study 32692805 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional intervention (IG) in women with obesity
Number of subjects: 4631
Study 32692805 — intervention group
Group type: COMPARATOR
Intervention: Routine care (CG) in women with obesity
Number of subjects: 4631
Study 35136911 — intervention group
Group type: EXPERIMENTAL
Intervention: cobas plasma separation card (PSC) specimens stored at temperatures from 25ºC to 42ºC for up to 28 days
Number of subjects: 30
Study 35136911 — intervention group
Group type: EXPERIMENTAL
Intervention: cobas plasma separation card (PSC) specimens
Number of subjects: 30
Study 33099855 — intervention group
Group type: EXPERIMENTAL
Intervention: Erector spinae plane (ESP) block with 30 ml 0.25% bupivacaine at the T8 level
Number of subjects: 40
Study 33099855 — intervention group
Group type: COMPARATOR
Intervention: Intravenous infusion of 50 mg of dexketoprofen trometamol (NSAID)
Number of subjects: 40
Study 33099855 — intervention group
Group type: EXPERIMENTAL
Intervention: Erector spinae plane (ESP) block
Number of subjects: 40
Study 32145173 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP therapy
Number of subjects: 159
Study 32145173 — intervention group
Group type: COMPARATOR
Intervention: Facetoplasty
Number of subjects: 159
Study 33687145 — intervention group
Group type: EXPERIMENTAL
Intervention: Purple potato extract rich in acylated anthocyanins (152 mg) and hydroxycinnamic acid conjugates (140 mg)
Number of subjects: 17
Study 33687145 — intervention group
Group type: EXPERIMENTAL
Intervention: Yellow potato meal with purple potato extract
Number of subjects: 17
Study 33687145 — intervention group
Group type: COMPARATOR
Intervention: Yellow potato meal without purple potato extract
Number of subjects: 17
Study 34108192 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% aqueous chlorhexidine gluconate (CHG)
Number of subjects: 308
Study 34108192 — intervention group
Group type: COMPARATOR
Intervention: 2% aqueous chlorhexidine gluconate (CHG)
Number of subjects: 308
Study 32715985 — intervention group
Group type: EXPERIMENTAL
Intervention: Cremophor RH 40
Number of subjects: 0
Study 32715985 — intervention group
Group type: COMPARATOR
Intervention: Unprocessed fexofenadine
Number of subjects: 0
Study 34966017 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganglion impar block (GIB)
Number of subjects: 68
Study 34966017 — intervention group
Group type: COMPARATOR
Intervention: Caudal epidural steroid injection (CESI)
Number of subjects: 68
Study 33886810 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein (WP) supplementation for 12 weeks
Number of subjects: 25
Study 33886810 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 25
Study 33211829 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher genetically predicted HDL-C levels
Number of subjects: 419649
Study 33211829 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher genetically predicted ApoA1 levels
Number of subjects: 419649
Study 33211829 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher genetically predicted LDL-C levels
Number of subjects: 419649
Study 33211829 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher genetically predicted ApoB levels
Number of subjects: 419649
Study 33211829 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher genetically predicted CHOL levels
Number of subjects: 419649
Study 33211829 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher genetically predicted non-HDL-C levels
Number of subjects: 419649
Study 33211829 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher genetically predicted TG levels
Number of subjects: 419649
Study 35449070 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-coated balloon angioplasty
Number of subjects: 0
Study 35449070 — intervention group
Group type: COMPARATOR
Intervention: Uncoated balloon angioplasty
Number of subjects: 0
Study 32808592 — intervention group
Group type: EXPERIMENTAL
Intervention: Inferior tibiofibular mobilization with movement (ITFMWM)
Number of subjects: 75
Study 32808592 — intervention group
Group type: COMPARATOR
Intervention: Placebo mobilization with movement
Number of subjects: 75
Study 32808592 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-injured ankle
Number of subjects: 75
Study 34401388 — intervention group
Group type: EXPERIMENTAL
Intervention: Oncokompas (web-based self-management application)
Number of subjects: 655
Study 616542428 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerol-enriched yeast culture (GY)
Number of subjects: 44
Study 616542428 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerol (G)
Number of subjects: 44
Study 616542428 — intervention group
Group type: COMPARATOR
Intervention: Control (no additive)
Number of subjects: 44
Study 35142355 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 191
Study 33863305 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane-based general anesthesia
Number of subjects: 340
Study 33863305 — intervention group
Group type: COMPARATOR
Intervention: Awake-local anesthesia
Number of subjects: 340
Study 32250135 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosocial spending (spending money on others)
Number of subjects: 5199
Study 32250135 — intervention group
Group type: COMPARATOR
Intervention: Personal spending (spending money on oneself)
Number of subjects: 5199
Study 32204980 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-assisted lumbar puncture (UALP)
Number of subjects: 166
Study 32204980 — intervention group
Group type: COMPARATOR
Intervention: Standard landmark-based lumbar puncture (SLP)
Number of subjects: 166
Study 34486810 — intervention group
Group type: EXPERIMENTAL
Intervention: Social cognitive skills groups
Number of subjects: 34
Study 34486810 — intervention group
Group type: COMPARATOR
Intervention: Facilitated play comparison groups
Number of subjects: 34
Study 32192496 — intervention group
Group type: EXPERIMENTAL
Intervention: LIG once weekly (QW)
Number of subjects: 64
Study 32192496 — intervention group
Group type: EXPERIMENTAL
Intervention: LIG twice weekly (BW)
Number of subjects: 64
Study 32192496 — intervention group
Group type: COMPARATOR
Intervention: Enrofloxacin and silver sulfadiazine twice daily (C)
Number of subjects: 64
Study 35951253 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-hour training in stimulant diversion prevention
Number of subjects: 76
Study 35951253 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual
Number of subjects: 76
Study 32029903 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (NTX) treatment for at least three months
Number of subjects: 93
Study 32029903 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (NTX) treatment
Number of subjects: 93
Study 32029903 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 93
Study 35012827 — intervention group
Group type: EXPERIMENTAL
Intervention: BTA injections into the subjacent orbicularis oris muscle (4 points group)
Number of subjects: 64
Study 35012827 — intervention group
Group type: COMPARATOR
Intervention: BTA injections into the bilateral nasolabial fold region (6 points group)
Number of subjects: 64
Study 33260274 — intervention group
Group type: EXPERIMENTAL
Intervention: Kindred intervention
Number of subjects: 30
Study 35085361 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Care Bridge (CCB) program consisting of case management, disease management, and home-based cardiac rehabilitation
Number of subjects: 306
Study 35085361 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 306
Study 33342522 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional $40 in monthly SNAP benefits per child under age 5 years (treatment group)
Number of subjects: 3088
Study 33342522 — intervention group
Group type: COMPARATOR
Intervention: Control group (no additional SNAP benefits)
Number of subjects: 3088
Study 34293933 — intervention group
Group type: EXPERIMENTAL
Intervention: IV esmolol
Number of subjects: 28
Study 34293933 — intervention group
Group type: COMPARATOR
Intervention: IV metoprolol
Number of subjects: 28
Study 32437787 — intervention group
Group type: EXPERIMENTAL
Intervention: Volumetric assessment of ECR using CBCT imaging and Amira software.
Number of subjects: 168
Study 32437787 — intervention group
Group type: EXPERIMENTAL
Intervention: Heithersay classification and treatment decision by independent evaluators.
Number of subjects: 168
Study 32437787 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical repair decision by independent evaluators.
Number of subjects: 168
Study 34481388 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 nm PS-NPs
Number of subjects: 1080
Study 34481388 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 µm PS-MPs
Number of subjects: 1080
Study 34481388 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 1080
Study 34888397 — intervention group
Group type: EXPERIMENTAL
Intervention: Visbiome ES
Number of subjects: 93
Study 34888397 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93